2-氨基-4-硝基苯甲酸乙酯 | 55204-24-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-氨基-4-硝基苯甲酸乙酯
• 英文名称: ethyl 2-amino-4-nitrobenzoate
• 英文别名: 2-carboethoxy-5-nitroaniline；2-amino-4-nitro-benzoic acid ethyl ester；2-Amino-4-nitro-benzoesaeure-aethylester；4-Nitro-anthranilsaeureaethylester；ethyl 6-amino-4-nitro benzoate；2-amino-4-nitro-ethylbenzoate；ethyl 4-nitroanthranilate
• CAS: 55204-24-5
• 化学式: C₉H₁₀N₂O₄
• 分子量: 210.189
• InChiKey: WTHFROVMUKFWCO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  98.1
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 海关编码：
  2922499990

反应信息

• 作为反应物：
  描述：

  2-氨基-4-硝基苯甲酸乙酯 以93的产率得到2-acetylamino-4-nitro-benzoic acid ethyl ester
  参考文献：
  名称：

  Quinolinone derivative and anti-allergic agent with said quinolinone

  摘要：

  本发明提供了7-氨基喹啉酮衍生物、其生理学上可接受的盐、以7-氨基喹啉酮衍生物或其生理学上可接受的盐为活性成分的抗过敏药物，以及7-硝基喹啉酮衍生物，其中7-氨基喹啉酮衍生物由下列通式（I）表示：##STR1## 其中R.sub.1是氢原子或烷基；R.sub.2和R.sub.3是不同的基团，每个基团从氢原子、酰基、烷基或烯基中选择；R.sub.4和R.sub.5是不同或相同的基团，每个基团从氢原子、酰基、烷基、烯基或苄基中选择；以及其生理学上可接受的盐。

  公开号：

  US05942521A1
• 作为产物：
  描述：

  N-(2-甲基-5-硝基苯基)乙酰胺 在 盐酸 、 potassium permanganate 、 乙醇 、 硫酸 作用下， 生成 2-氨基-4-硝基苯甲酸乙酯
  参考文献：
  名称：

  Wheeler; Barnes, American Chemical Journal, 1898, vol. 20, p. 222

  摘要：

  DOI：

文献信息

• 2-substituted-4H-3, 1-benzoxazin-4-ones and benzthiazin-4-ones as
  申请人：Warner-Lambert Company

  公开号：US05652237A1

  公开（公告）日：1997-07-29

  This invention concerns certain 2-substituted-3,1-benzoxazin-4-ones and benzthiazinones as complement Clr protease inhibitors and antiinflammatory agents, pharmaceutical compositions containing them, methods of using them, and processes for their preparation.

  这项发明涉及某些2-取代-3,1-苯并噁嗪-4-酮和苯并噻嗪酮作为补体Clr蛋白酶抑制剂和抗炎药物，包含它们的药物组合物，使用它们的方法以及它们的制备方法。
• Dioxo-tetrahydroquinoline derivatives
  申请人：Merck Sharp & Dohme, Limited

  公开号：US05268378A1

  公开（公告）日：1993-12-07

  A class of 2,4-dioxo-1,2,3,4-tetrahydroquinoline derivatives, substituted at the 3-position by a range of carbonyl-containing substituents or by a five- or six-membered heteroaromatic moiety, are selective non-competitive antagonists of NMDA receptors and/or are antagonists of AMPA receptors, and are therefore of utility in the treatment of conditions, such as neurodegenerative disorders, convulsions or schizophrenia, which require the administration of an NMDA and/or AMPA antagonist.

  一类2,4-二氧代-1,2,3,4-四氢喹啉衍生物，其在3位被一系列含羰基取代基团或五元或六元杂芳基取代，是NMDA受体的选择性非竞争性拮抗剂和/或是AMPA受体的拮抗剂，因此在治疗神经退行性疾病、癫痫或精神分裂症等需要给予NMDA和/或AMPA拮抗剂的情况下具有实用价值。
• Studies on the rearrangement of <i>ortho</i>-nitrobenzylidenemalonates and their Analogues to 2-aminobenzoate derivatives
  作者：Elzbieta Lewandowska、Stefan Kinastowski、Stanislaw F Wnuk

  DOI：10.1139/v02-010

  日期：2002.2.1

  Reaction of the diethyl 2-nitro-4-(trifluoromethyl)benzylidenemalonate with diethylamine in alcohols resulted in the reduction of the nitro group and the oxidation of the vinylic carbon attached to the phenyl ring. Simultaneous migration of the malonic fragment gave the appropriate 2-amino-4-(trifluoromethyl)benzoate esters. The presence of at least two nitro groups, or one nitro group and trifluoromethyl group on the phenyl ring, attached to the α-carbon and strongly electron withdrawing substituents at the β-carbon (CO₂Et, CN) in ortho-nitrobenzylidene systems is necessary for this reductive–oxidative rearrangement to proceed. Reaction of nitrocinnamates with thiols in the presence of triethylamine in tetrahydrofuran gave Michael addition products with different regioselectivity of addition. Ethyl 2-nitrocinnamate undergoes standard β-addition of thiols to a carbon–carbon double bond. However, 2,4-dinitro- and 2,4,6-trinitrocinnamates undergo α-addition of thiols, indicating that the presence of two nitro groups on the phenyl ring can reverse polarity of the carbon–carbon double bond in cinnamate acceptors.Key words: abnormal Michael reactions, aromatic nitro compounds, benzylidene compounds, rearrangements.

  二乙基2-硝基-4-(三氟甲基)苯基丙烯基丙二酸二乙酯在醇中与二乙胺反应，导致硝基团的还原和连接到苯环上的烯基碳的氧化。马隆酸残基的同时迁移产生适当的2-氨基-4-(三氟甲基)苯甲酸酯。对于这种还原-氧化重排反应，苯环上至少存在两个硝基，或一个硝基和三氟甲基团，连接到α-碳，并且在β-碳（CO₂Et，CN）上具有强电子吸引取代基在邻硝基苯基丙烯酮系统中是必要的。硝基肉桂酸酯在四氢呋喃中与硫醇在三乙胺存在下反应，产生具有不同加成区域选择性的迈克尔加成产物。乙基2-硝基肉桂酸酯经历了硫醇对碳-碳双键的标准β-加成。然而，2,4-二硝基和2,4,6-三硝基肉桂酸酯经历了硫醇的α-加成，表明苯环上存在两个硝基可以颠倒肉桂酸受体中碳-碳双键的极性。关键词：异常迈克尔反应，芳香硝基化合物，苄亚甲基化合物，重排。
• Bicyclic substituted hexahydrobenz \x9be! isoindole alpha-1 adrenergic
  申请人：Abbott Laboratories

  公开号：US05792767A1

  公开（公告）日：1998-08-11

  The present invention relates to a compound of the formula ##STR1## and the pharmaceutically acceptable salts thereof wherein W is a bicyclic heterocyclic ring system. The compounds are .alpha.-1 adrenergic antagonists and are useful in the treatment of BPH; also disclosed are .alpha.-1 antagonist compositions and a method for antagonizing .alpha.-1 receptors and treating BPH.

  本发明涉及以下公式的化合物##STR1##及其药用可接受的盐，其中W是一个双环杂环环系统。这些化合物是α-1肾上腺素受体拮抗剂，在治疗BPH方面具有用途；还公开了α-1拮抗剂组合物和对抗α-1受体以及治疗BPH的方法。
• Quinolinone derivative, method for preparing the same, and anti-allergic
  申请人：Dainippon Ink and Chemicals, Inc.

  公开号：US06136822A1

  公开（公告）日：2000-10-24

  The present invention relates to a simple method for preparing a quinolinone derivative, which is effective as a medicine, e.g., as an agent for treating allergic diseases and the like; novel amide derivatives effective as an intermediate in the method; novel quinolinone derivatives obtained according to the method; and an anti-allergic agent containing a quinolinone derivative and/or physiological salt of the same as the active ingredients. The quinolinone derivative is expressed by the following general formula (II); and the method is characterized in that an amide derivative, expressed by the following formula (I), is reacted with a basic agent, followed by intramolecular ring formation: ##STR1## wherein R.sub.1 represents a hydrogen atom, an alkyl group, an alkyl group containing a hydroxyl group an alkenyl group, or an aryl group; R.sub.2 represents an alkyl group, an alkenyl group, an aryl group, or an aralkyl group; R.sub.3 represents a reactive carboxyl group; and R.sub.4 to R.sub.7 represent, respectively and independently, a hydrogen atom; a hydroxyl group; an alkyl group; an alkoxy group; an alkenyl group; an alkenyloxy group; an aryl group; an aryloxy group; an aralkyloxy group; a R.sub.8 R.sub.9 N group wherein R.sub.8 and R.sub.9 represent, respectively and independently, a hydrogen atom, an alkyl group, an alkenyl group an aralkyl group, or an acyl group; a nitro group; or a R.sub.10 OOC group wherein R.sub.10 represents a hydrogen atom, an alkyl group, an alkenyl group, an aryl group, or an aralkyl group; ##STR2## wherein R.sub.1, R.sub.2 and R.sub.4 to R.sub.7 represent, respectively, the same constituents as described in formula (I).

  本发明涉及一种简单的制备喹啉酮衍生物的方法，该方法作为药物具有有效性，例如作为治疗过敏性疾病等的药剂；作为该方法中的中间体有效的新酰胺衍生物；根据该方法获得的新喹啉酮衍生物；以及含有喹啉酮衍生物和/或其生理盐作为活性成分的抗过敏剂。喹啉酮衍生物由以下通用式（II）表示；该方法的特征在于，将由以下式（I）表示的酰胺衍生物与碱性试剂反应，然后进行分子内环形成：其中R.sub.1代表氢原子、烷基、含有羟基的烷基、烯基或芳基；R.sub.2代表烷基、烯基、芳基或芳基烷基；R.sub.3代表反应性羧基；R.sub.4到R.sub.7分别且独立地代表氢原子；羟基；烷基；烷氧基；烯基；烯氧基；芳基；芳氧基；芳基烷氧基；R.sub.8 R.sub.9 N基团，其中R.sub.8和R.sub.9分别且独立地代表氢原子、烷基、烯基、芳基烷基或酰基；硝基团；或R.sub.10 OOC基团，其中R.sub.10代表氢原子、烷基、烯基、芳基或芳基烷基；其中R.sub.1、R.sub.2和R.sub.4到R.sub.7分别代表与式（I）中描述的相同的成分。